Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Green

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Journal of the American Academy of Dermatology|February 19, 2020
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trialBrandon Kirsch, Stacy Smith, Joel Cohen, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Journal of the American Academy of Dermatology|August 3, 2021
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trialLinda Stein Gold, Kim Papp, David Pariser, et al.
Journal of Drugs in Dermatology : JDD|March 5, 2024
Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% GelJulie C Harper, Leon H Kircik, Michael Gold, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|January 25, 2013
Building a strategic framework for comparative effectiveness research in complementary and integrative medicineClaudia M Witt, Margaret Chesney, Richard Gliklich, et al.
Dermatology and Therapy|May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb TrialNada Elbuluk, April W Armstrong, Ronald Vender, et al.
Journal of Drugs in Dermatology : JDD|May 20, 2010
Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgarisEmil Tanghetti, Sunil Dhawan, Lawrence Green, et al.
Chembiochem : a European Journal of Chemical Biology|July 29, 2025
Structures of "Tyrosine-IRED" IR91 from Kribbella flavida in Complex with a Reductive Amination Substrate and ProductKrishnan Srinivas, Amelia K Gilio, Mahima Sharma, et al.
JAMA Dermatology|August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical TrialApril W Armstrong, Melinda Gooderham, Charles Lynde, et al.
BMJ (Clinical Research Ed.)|July 28, 2011
How should we define health?Machteld Huber, J André Knottnerus, Lawrence Green, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Journal of the American Academy of Dermatology|February 19, 2020
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trialBrandon Kirsch, Stacy Smith, Joel Cohen, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Journal of the American Academy of Dermatology|August 3, 2021
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trialLinda Stein Gold, Kim Papp, David Pariser, et al.
Journal of Drugs in Dermatology : JDD|March 5, 2024
Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% GelJulie C Harper, Leon H Kircik, Michael Gold, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|January 25, 2013
Building a strategic framework for comparative effectiveness research in complementary and integrative medicineClaudia M Witt, Margaret Chesney, Richard Gliklich, et al.
Dermatology and Therapy|May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb TrialNada Elbuluk, April W Armstrong, Ronald Vender, et al.
Journal of Drugs in Dermatology : JDD|May 20, 2010
Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgarisEmil Tanghetti, Sunil Dhawan, Lawrence Green, et al.
Chembiochem : a European Journal of Chemical Biology|July 29, 2025
Structures of "Tyrosine-IRED" IR91 from Kribbella flavida in Complex with a Reductive Amination Substrate and ProductKrishnan Srinivas, Amelia K Gilio, Mahima Sharma, et al.
JAMA Dermatology|August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical TrialApril W Armstrong, Melinda Gooderham, Charles Lynde, et al.
BMJ (Clinical Research Ed.)|July 28, 2011
How should we define health?Machteld Huber, J André Knottnerus, Lawrence Green, et al.
Pageof 6